The story of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated significant gains, the lapse of its exclusive rights opened the floodgates to generic versions, dramatically reducing market share. This poses a particular dilemma for drug manufacturers depending on similar blockbuster offer

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. Initially a blockbuster drug, yielding billions in sales , its intellectual property lapse created a wave of lower-priced alternatives , significantly diminishing its position . While certain pharmaceutical companies may seek to capitalize on similar